AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020

Author's Avatar
May 14, 2020
Article's Main Image

Ended the First Quarter of 2020 with Cash, Cash Equivalentsand Marketable Securities of $31.1 Million